RANCHO CORDOVA, Calif., and BARCELONA, Spain, May 22 /PRNewswire/ -- Volcano Corporation today announced its planned activities for the EuroPCR 2007 meeting to be held in Barcelona from May 22nd - 25th. In keeping with the scientific and educational tradition of EuroPCR, Volcano will focus its activities on live case demonstrations of new products and technologies in development, including the s5i Bedside Touchpad Controller and the advanced functionality options that will enable the high frequency Revolution(TM) 45 MHz IVUS Catheter and the Volcano Pressure Guide Wires to operate on the s5i integrated platform. The latter is a late stage development program that will enable physicians to choose the desired diagnostic tool for each individual patient, from high frequency 45 MHz rotational IVUS to easy-to-use 20 MHz digital IVUS, to intermediate lesion analysis with FFR. All of these technologies will operate on the same s5i integrated platform.
New Product Launches:
During EuroPCR 2007, Volcano will display a number of new products and technologies:
s5i Bedside Touchpad Controller -- Full-function Touchpad controller enables control of the s5i imaging system from the convenience of the sterile field -- Designed to operate underneath a sterile drape -- Simple user interface complements plug-and-play digital imaging with the Eagle Eye(R) Gold IVUS Imaging Catheter -- Same controller will be used with the 45 MHz Revolution(TM) and s5-ffr options when they become available Revolution(TM) 45 MHz Rotational IVUS Imaging Catheter -- High frequency IVUS catheter for improved near-field imaging -- Easy-to-use, reusable pullback device -- Automatic pullback inside of a protective sheath s5-Revo & s5-ffr (Late Stage Development Products) -- s5-Revo: Advanced functionality option enables the high frequency Revolution(TM) 45 MHz Rotational IVUS Imaging Catheter to operate on the same s5i integrated platform as the Digital Eagle Eye(R) Gold IVUS Catheter -- s5-ffr: Advanced functionality option enables FFR measurements on the same s5i integrated IVUS platform using the Volcano Pressure wires -- These options will make the Volcano s5i the only system capable of running both rotational and digital IVUS, as well as FFR, all on the same integrated platform
Live Case Transmissions:
Volcano and its clinical collaborators are working to provide live case demonstrations of these and other Volcano technologies during the EuroPCR meeting to show their practical use and utility in a wide variety of clinical situations. Live case demonstrations are planned from six transmitting sites in Europe, the US and Asia Pacific. Expected live case cities include: Toulouse, Massy, Aalst, Rotterdam, New York and Seoul.
Special Live Case Focus Session:
In addition to the many live case demonstrations planned during the daily scientific sessions at EuroPCR, Volcano is sponsoring a Case Review Session and co-sponsoring a Focus Session with GE Healthcare. Both sessions will be highlighting the full array of Volcano technologies during routine PCI.
The Case Review Session will be chaired by B. de Bruyne with speakers A. Lerman, J. de la Torre, T. Akasaka, M. Foster, C. von Birgelen. The learning objective is to better understand the clinical value of two complementary lesion assessment techniques: intra-vascular ultrasound includingVH(TM) IVUS tissue characterization and fractional flow reserve (FFR). This program is scheduled for Wednesday May 23rd, 16:30 - 18:00, Room 118/119 The Focus Session will be co-sponsored with GE Healthcare, and chaired by M-C. Morice with collaboration of R. Erbel, T. Lefevre, Y. Louvard , A. Ohanessian, W. Wijns. The speakers will discuss the recent advances in imaging (IVUS, MSCT and their integration) benefit analysis and intervention of complex bifurcation lesions. This program is scheduled for Thursday, 24 May, 09:00-11:30, Room 9.
Exhibition Booth and Hands-On Demonstrations:
For EuroPCR this year, Volcano’s booth will include hands-on demonstrations of these new products. For EuroPCR attendees, please visit us at booth F16, Centre de Convencions, Internacional de Barcelona (The Forum - CCIB), May 22- 25, 2007
Scott Huennekens, Volcano’s President & CEO commented, “This is a very exciting time for Volcano. Physicians are demanding a more complete patient diagnosis to drive their therapeutic decisions and improve the safety and efficacy of patient outcomes. To meet this physician and patient need, Volcano is pulling previously disconnected diagnostic modalities together into a more efficient and streamlined comprehensive tool. Volcano’s different levels of partnerships with GE Healthcare and Philips have been an important first step in combining the accessibility of angiography with the detail of IVUS into an integrated workflow. Volcano is looking forward to delivering the first system capable of combining the benefits of our three primary diagnostic tools, digital IVUS, high-frequency IVUS, and FFR, all onto the same integrated platform. We will continue our research and development into co-registration with Angio and CTA, as well as Intra-Cardiac Echo (ICE) to again make these very diverse yet complementary diagnostic tools accessible on one platform to every cath lab.”
About Volcano Corporation
Volcano Corporation offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart diseases and guide optimal therapies. The company’s intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH(TM) IVUS tissue characterization. Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires. Currently, more than 2,600 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. For more information, visit the company’s website at http://www.volcanocorp.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano’s business that are not historical facts may be considered “forward-looking statements,” including statements regarding the company’s success and timing of product development and new product introductions, the expected performance enhancements of its products, and market conditions and expectations. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties, which may cause Volcano’s results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company’s annual report on Form 10-K, quarterly report on Form 10-Q, and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Volcano Corporation
CONTACT: Company Contact, +1-916-638-8008, info@volcanocorp.com; UnitedStates, Joe Burnett, Director of Marketing of Volcano Corporation,+1-916-638-8008, fax, +1-916-638-8112; Japan, Junichi Osawa, President &Managing Director, or Koji Osaka, General Manager, both of VolcanoCorporation, +81-3-5791-2616; or Europe & Middle East, Michel Lussier, VicePresident, Europe, Africa, Middle-East, of Volcano Europe SA/NV, +32 475 8000 97, fax, +32 2 679 10 72
Web site: http://www.volcanocorp.com/
